单用索拉非尼治疗晚期肝细胞癌患者的暂时缓解- 1例报告和文献复习

S. Elder, Yixing Jiang
{"title":"单用索拉非尼治疗晚期肝细胞癌患者的暂时缓解- 1例报告和文献复习","authors":"S. Elder, Yixing Jiang","doi":"10.15761/crr.1000180","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC) is a primary liver tumor which has been increasing in incidence over the past several years [1], and is the second leading cause of cancer death in the world [2]. Advanced HCC usually carries a poor prognosis. Over the past decade, systemic therapy for HCC has been evolving rapidly offering more therapeutic options and longer survival for those with incurable HCC. Here, we report a case of advanced HCC treated with single agent sorafenib and achieved complete radiographic response. In this article, we also provide a summary of current status of systemic therapy for HCC. *Correspondence to: Yixing Jiang, Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, USA, E-mail: yjiang@umm.edu","PeriodicalId":91850,"journal":{"name":"Cancer reports and reviews","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Temporary remission of advanced hepatocellular carcinoma in a patient treated with sorafenib therapy alone - A case report and literature review\",\"authors\":\"S. Elder, Yixing Jiang\",\"doi\":\"10.15761/crr.1000180\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hepatocellular carcinoma (HCC) is a primary liver tumor which has been increasing in incidence over the past several years [1], and is the second leading cause of cancer death in the world [2]. Advanced HCC usually carries a poor prognosis. Over the past decade, systemic therapy for HCC has been evolving rapidly offering more therapeutic options and longer survival for those with incurable HCC. Here, we report a case of advanced HCC treated with single agent sorafenib and achieved complete radiographic response. In this article, we also provide a summary of current status of systemic therapy for HCC. *Correspondence to: Yixing Jiang, Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, USA, E-mail: yjiang@umm.edu\",\"PeriodicalId\":91850,\"journal\":{\"name\":\"Cancer reports and reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer reports and reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/crr.1000180\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports and reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/crr.1000180","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

肝细胞癌(HCC)是一种原发性肝脏肿瘤,其发病率在过去几年中呈上升趋势,是全球癌症死亡的第二大原因。晚期HCC通常预后较差。在过去的十年中,HCC的全身治疗发展迅速,为无法治愈的HCC患者提供了更多的治疗选择和更长的生存期。在这里,我们报告了一例晚期HCC单药索拉非尼治疗并获得完全放射学反应。在本文中,我们也对肝细胞癌的全身治疗现状进行了总结。*通讯:美国巴尔的摩马里兰大学医学中心蒋宜兴,Marlene and Stewart Greenebaum癌症中心,E-mail: yjiang@umm.edu
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Temporary remission of advanced hepatocellular carcinoma in a patient treated with sorafenib therapy alone - A case report and literature review
Hepatocellular carcinoma (HCC) is a primary liver tumor which has been increasing in incidence over the past several years [1], and is the second leading cause of cancer death in the world [2]. Advanced HCC usually carries a poor prognosis. Over the past decade, systemic therapy for HCC has been evolving rapidly offering more therapeutic options and longer survival for those with incurable HCC. Here, we report a case of advanced HCC treated with single agent sorafenib and achieved complete radiographic response. In this article, we also provide a summary of current status of systemic therapy for HCC. *Correspondence to: Yixing Jiang, Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, USA, E-mail: yjiang@umm.edu
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Curatively treated pancreatic metastases of intimal sarcoma: first case report Emerging diagnostic and therapeutic applications of non-ionising electromagnetic radiations in Oncology Exploring FLOT- and FOLFOX-Based total neoadjuvant therapy for patients with locally advanced gastroesophageal cancers Clinical, analytical and histological factors relating to patients diagnosed with lung cancer, head and neck cancer and melanoma treated with immunotherapy in the last 5 years of a university hospital The Prevalence of Positive Family History of Malignancy Among Patients with Gynecologic Cancers in the Kingdom of Bahrain: A Retrospective Cross-sectional Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1